Published in NDT Plus on January 01, 2009
Biosimilars-why terminology matters. Nat Biotechnol (2011) 1.73
Biosimilars: Implications for health-system pharmacists. Am J Health Syst Pharm (2013) 1.36
Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol (2012) 1.34
The economic pressures for biosimilar drug use in cancer medicine. Target Oncol (2012) 1.34
Biosimilar granulocyte-colony-stimulating factor for healthy donor stem cell mobilization: need we be afraid? Transfusion (2014) 1.18
An Overview of Current Regulatory Requirements for Approval of Biosimilar Insulins. Diabetes Technol Ther (2015) 1.09
Analysis of host-cell proteins in biotherapeutic proteins by comprehensive online two-dimensional liquid chromatography/mass spectrometry. MAbs (2012) 1.08
Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J (2013) 1.02
Chapter 3: Use of ESAs and other agents to treat anemia in CKD. Kidney Int Suppl (2011) (2012) 1.00
Etanercept biosimilars. Rheumatol Int (2014) 0.93
Barriers to the Access and Use of Rituximab in Patients with Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: A Physician Survey. Pharmaceuticals (Basel) (2014) 0.91
Biosimilars in IBD: from theory to practice. Nat Rev Gastroenterol Hepatol (2016) 0.91
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int (2016) 0.89
Barriers to the Use of Trastuzumab for HER2+ Breast Cancer and the Potential Impact of Biosimilars: A Physician Survey in the United States and Emerging Markets. Pharmaceuticals (Basel) (2014) 0.86
Discovery and basic pharmacology of erythropoiesis-stimulating agents (ESAs), including the hyperglycosylated ESA, darbepoetin alfa: an update of the rationale and clinical impact. Eur J Clin Pharmacol (2010) 0.84
Overcoming Barriers to the Market Access of Biosimilars in the European Union: The Case of Biosimilar Monoclonal Antibodies. Front Pharmacol (2016) 0.82
Study design: two long-term observational studies of the biosimilar filgrastim Nivestim™ (Hospira filgrastim) in the treatment and prevention of chemotherapy-induced neutropenia. BMC Cancer (2013) 0.81
Epoetin zeta in the management of anemia associated with chronic kidney disease, differential pharmacology and clinical utility. Biologics (2014) 0.80
Update on the safety and bioequivalence of biosimilars - focus on enoxaparin. Drug Healthc Patient Saf (2013) 0.80
The evolving role of biosimilars in haematology-oncology: a practical perspective. Ther Adv Hematol (2015) 0.77
The constrained prescription, interchangeability and substitution of biosimilars. Nat Biotechnol (2015) 0.77
Biosimilars in 3D: definition, development and differentiation. Bioengineered (2013) 0.76
Biosimilar structural comparability assessment by NMR: from small proteins to monoclonal antibodies. Sci Rep (2016) 0.75
Recent advances in (therapeutic protein) drug development. F1000Res (2017) 0.75
Immunogenicity of Biotherapeutics: Causes and Association with Posttranslational Modifications. J Immunol Res (2016) 0.75
[Regulatory aspects of biosimilars : Myths and facts]. Z Rheumatol (2015) 0.75
Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure. Nephrol Dial Transplant (2004) 4.27
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
The challenge of biosimilars. Ann Oncol (2007) 2.28
Lessons from Eprex for biogeneric firms. Nat Biotechnol (2003) 2.22
Factors influencing the immunogenicity of therapeutic proteins. Nephrol Dial Transplant (2005) 2.07
Biotechnology and drug discovery: from bench to bedside. South Med J (2003) 2.04
Characterizing biological products and assessing comparability following manufacturing changes. Nat Biotechnol (2004) 2.04
Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol (2006) 1.98
EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer (2006) 1.96
Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. Curr Pharm Biotechnol (2002) 1.81
Immunogenicity of biopharmaceuticals. Nephrol Dial Transplant (2006) 1.74
Pure red cell aplasia due to follow-on epoetin. Kidney Int (2008) 1.69
Interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm Res (2005) 1.64
Biosimilars: how similar or dissimilar are they? Nephrology (Carlton) (2006) 1.62
Biophysical comparability of the same protein from different manufacturers: a case study using Epoetin alfa from Epogen and Eprex. J Pharm Sci (2006) 1.60
Follow-on biologics: challenges of the "next generation". Nephrol Dial Transplant (2005) 1.52
Micelle-associated protein in epoetin formulations: aA risk factor for immunogenicity? Pharm Res (2003) 1.34
Biosimilar epoetins: an analysis based on recently implemented European medicines evaluation agency guidelines on comparability of biopharmaceutical proteins. Pharmacotherapy (2005) 1.31
Comparative testing and pharmacovigilance of biosimilars. Nephrol Dial Transplant (2006) 1.25
Human immune response to recombinant human proteins. J Pharm Sci (2001) 1.23
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant (2005) 1.16
Immunologic mechanisms of EPO-associated pure red cell aplasia. Best Pract Res Clin Haematol (2005) 1.15
The first biosimilar epoetin: but how similar is it? Clin J Am Soc Nephrol (2007) 1.11
Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol (2008) 1.11
Epoetin-induced autoimmune pure red cell aplasia. J Am Soc Nephrol (2005) 1.05
Pure red-cell aplasia and recombinant erythropoietin. N Engl J Med (2002) 0.95
Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol (2005) 0.93
European regulatory guidelines for biosimilars. Nephrol Dial Transplant (2006) 0.89
Immunogenicity of rDNA-derived pharmaceuticals. Trends Pharmacol Sci (2002) 0.88